Before the U.S. stock market opened on Tuesday, January 31, the U.S. pharmaceutical giant Pfizer announced its fourth quarter and full-year results for 2022, and announced its 2023 performance guidance. In 2022, Pfizer’s revenue will reach a record US$100.3 billion, nearly six of which will be contributed by new crown vaccines and drugs. As the new crown epidemic fades, Pfizer expects its annual revenue to drop by at least 30% this year, and its earnings per share will be cut in half. | Related Reading (Wall Street Insights)
This article is reproduced from: https://www.fortunechina.com/jingxuan/26445.htm
This site is only for collection, and the copyright belongs to the original author.